In-house IP roundup: SPC waiver will drive innovator investment in secondary patents; EU vote on driverless cars is disastrous for licensing budgets

Drugs

UCB, GSK and other innovator drug firms explain how the EU’s SPC Manufacturing Waiver might drive larger investments in secondary patent fortresses for new products and strain resources on monitoring and litigation as they seek to interpret the legislation. Read more ...

Money

Telecoms and automotive firms say that proposed EU legislation to adopt Wi-Fi as the standard for driverless cars will force automotive makers to use an outdated technology and put them at a competitive disadvantage to the rest of the world. Read more ...

UK Actavis ruling raises clarity on dosage regimen patents, say drug companies

As governments face growing concern over rising drug prices, in-house counsel from innovator and generic pharmaceutical companies re-examine their strategies when it comes to injunctions. Read more ...

The Patent Prosecution Highway is gaining popularity because of its cost-saving benefits, but it is not always the right tool for the job, according to in-house counsel. Read more ...